Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer

• Published in: Journal of medicinal chemistry 2024-01, Vol.67 (2), p.1481-1499
• Main Authors: Fang, Wei, Zheng, Jianwei, Deng, Lin, An, Yana, Rong, Deqin, Wei, Jianwei, Xiong, Xiao-Feng, Wang, Junjian, Wang, Yuanxiang
• Format: Article
• Language: English
• Subjects: Animals; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Prostatic Neoplasms, Castration-Resistant - metabolism; Receptors, Androgen - metabolism; Structure-Activity Relationship; Xenograft Model Antitumor Assays
• ISSN: 0022-2623; 1520-4804; 1520-4804
• DOI: 10.1021/acs.jmedchem.3c02063

Nuclear receptor receptor-related orphan receptor γ (RORγ) is a ligand-dependent transcription factor and has been established as a key player in castration-resistant prostate cancers (CRPC) by driving androgen receptor (AR) overexpression, representing a potential therapeutical target for advanced prostate cancers. Here, we report the identification of the first-in-class RORγ covalent inhibitor 29 via the structure-based drug design approach following structure–activity relationship (SAR) exploration. Mass spectrometry assay validated its covalent inhibition mechanism. Compound 29 significantly inhibited RORγ transcriptional activity and remarkably suppressed the expression levels of AR and AR-targeted genes. Compound 29 also exhibited much superior activity in inhibiting the proliferation and colony formation and inducing apoptosis of the CRPC cell lines relative to the positive control 2 and noncovalent control 33. Importantly, it markedly suppressed the tumor growth in a 22Rv1 mouse tumor xenograft model with good safety. These results clearly demonstrate that 29 is a highly potent and selective RORγ covalent inhibitor.